Dianthus Therapeutics, Inc. /DE/ (DNTH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 34.39M USD | Liabilities, Current |
| Cash and equivalents | 110.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 106.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $34.39M | $110.55M | (m) | $106.00K | (m) | (m) |
| 2026-03-31 | $915.93M | $38.28M | $627.67M | $287.03M | $1.23M | (m) | 23.93× |
| 2025-12-31 | (m) | $30.73M | $51.09M | (m) | $52.00K | (m) | (m) |
| 2025-09-30 | (m) | $23.86M | $55.98M | (m) | $5.00M | (m) | (m) |
| 2025-06-30 | (m) | $20.09M | $13.24M | (m) | $39.00K | (m) | (m) |
| 2025-03-31 | (m) | $16.95M | $10.12M | (m) | $1.00M | (m) | (m) |
| 2024-12-31 | (m) | $18.45M | $22.79M | (m) | $807.00K | (m) | (m) |
| 2024-09-30 | (m) | $15.71M | $33.67M | (m) | $1.39M | (m) | (m) |
| 2024-06-30 | (m) | $10.03M | $314.17M | (m) | $840.00K | (m) | (m) |
| 2024-03-31 | (m) | $8.96M | $329.72M | (m) | $435.00K | (m) | (m) |
| 2023-12-31 | (m) | $9.63M | $132.32M | (m) | $294.00K | (m) | (m) |
| 2023-09-30 | (m) | $13.08M | $157.28M | (m) | $232.00K | (m) | (m) |
| 2023-06-30 | (m) | $4.03M | $62.63M | $14.96M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.98M | $48.52M | $29.68M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $14.55M | $57.63M | $54.41M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $12.92M | $59.03M | $69.26M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $11.26M | $54.83M | $84.59M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $14.09M | $71.77M | $84.84M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $10.86M | $131.65M | $45.28M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $10.15M | $157.54M | $35.08M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $11.08M | $155.03M | $52.77M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $9.21M | $49.29M | $83.00M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $11.43M | $58.15M | $90.68M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $9.86M | $141.68M | $20.05M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $10.37M | $136.29M | $40.21M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $12.70M | $74.93M | $55.47M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $14.12M | $65.07M | $80.66M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $9.63M | $85.51M | $75.06M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $9.94M | $33.11M | $139.16M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $7.92M | $31.24M | $96.07M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $10.42M | $58.34M | $84.22M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $11.93M | $159.67M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.61M | $173.43M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $4.14M | $51.40M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $59.95M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $63.78M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $4.51M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |